Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ] - Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
Thu, September 2, 2010

Ironwood Pharmaceuticals Announces Conference Call to Discuss Positive Linaclotide Phase 3 IBS-C Results


//health-fitness.news-articles.net/content/2010/ .. -positive-linaclotide-phase-3-ibs-c-results.html
Published in Health and Fitness on Monday, September 13th 2010 at 14:50 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ Ironwood Pharmaceuticals, Inc. ] (NASDAQ: IRWD) announced it will host a conference call and webcast today at 6:00 p.m. Eastern Time to discuss the positive top-line results of its Phase 3 clinical trial of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). Individuals interested in participating in the call should dial (888) 215-6825 (U.S. and Canada) or (913) 312-0844 (international) using conference ID number 4215125. To access the webcast, please visit the Investors section of Ironwooda™s website at [ www.ironwoodpharma.com ] at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting September 13, 2010 at 9:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on September 27, 2010. To listen to the replay, dial (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) using conference ID number 4215125. An archived version of the event will be available on Ironwooda™s website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwooda™s GCaC agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBSaC) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.


Publication Contributing Sources